378 related articles for article (PubMed ID: 10767724)
1. Nicotinamide prevents the development of diabetes in the cyclophosphamide-induced NOD mouse model by reducing beta-cell apoptosis.
O'Brien BA; Harmon BV; Cameron DP; Allan DJ
J Pathol; 2000 May; 191(1):86-92. PubMed ID: 10767724
[TBL] [Abstract][Full Text] [Related]
2. BCG vaccination prevents insulin-dependent diabetes mellitus (IDDM) in NOD mice after disease acceleration with cyclophosphamide.
Qin HY; Singh B
J Autoimmun; 1997 Jun; 10(3):271-8. PubMed ID: 9218754
[TBL] [Abstract][Full Text] [Related]
3. Beta-cell apoptosis is responsible for the development of IDDM in the multiple low-dose streptozotocin model.
O'Brien BA; Harmon BV; Cameron DP; Allan DJ
J Pathol; 1996 Feb; 178(2):176-81. PubMed ID: 8683386
[TBL] [Abstract][Full Text] [Related]
4. [Inhibition of islet beta cell apoptosis and prevention diabetes by subcutaneous administration of insulin in NOD mice].
Jiang TJ; Zhou ZG; Su H
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2006 Aug; 31(4):499-504. PubMed ID: 16951506
[TBL] [Abstract][Full Text] [Related]
5. Apoptosis and beta-cell destruction in pancreatic islets of NOD mice with spontaneous and cyclophosphamide-accelerated diabetes.
Augstein P; Elefanty AG; Allison J; Harrison LC
Diabetologia; 1998 Nov; 41(11):1381-8. PubMed ID: 9833948
[TBL] [Abstract][Full Text] [Related]
6. Analysis of action mechanism of lymphotoxin in prevention of cyclophosphamide-induced diabetes in NOD mice.
Takahashi K; Satoh J; Sagara M; Zhu XP; Muto G; Muto Y; Fukuzawa M; Nishimura S; Miyaguchi S; Toyata T
J Autoimmun; 1995 Jun; 8(3):335-46. PubMed ID: 7575995
[TBL] [Abstract][Full Text] [Related]
7. Immunolocalization of monocyte chemoattractant protein-1 in islets of NOD mice during cyclophosphamide administration.
Reddy S; Bai Y; Robinson E; Ross J
Ann N Y Acad Sci; 2006 Oct; 1079():103-8. PubMed ID: 17130538
[TBL] [Abstract][Full Text] [Related]
8. Protection from experimental autoimmune diabetes in the non-obese diabetic mouse with soluble interleukin-1 receptor.
Nicoletti F; Di Marco R; Barcellini W; Magro G; Schorlemmer HU; Kurrle R; Lunetta M; Grasso S; Zaccone P; Meroni P
Eur J Immunol; 1994 Aug; 24(8):1843-7. PubMed ID: 8056041
[TBL] [Abstract][Full Text] [Related]
9. [Recombinant human IGF-1 prevents type 1 diabetes in female non-obese diabetic mice].
Liu F; Yu M; Zhu Q
Zhonghua Yu Fang Yi Xue Za Zhi; 2000 Sep; 34(5):281-3. PubMed ID: 11372396
[TBL] [Abstract][Full Text] [Related]
10. Prevention of diabetes in the nonobese diabetic mouse by oral immunological treatments. Comparative efficiency of human insulin and two bacterial antigens, lipopolysacharide from Escherichia coli and glycoprotein extract from Klebsiella pneumoniae.
Saï P; Rivereau AS
Diabetes Metab; 1996 Oct; 22(5):341-8. PubMed ID: 8896996
[TBL] [Abstract][Full Text] [Related]
11. Effect of nicotinamide on experimental induced diabetes.
Alenzi FQ
Iran J Allergy Asthma Immunol; 2009 Mar; 8(1):11-8. PubMed ID: 19279354
[TBL] [Abstract][Full Text] [Related]
12. [Mechanisms of human glutamic acid decarboxylase 65 DNA vaccine preventing diabetes in non-obese diabetic mice].
Luo JH; Zhou ZG; Jiang TJ; Pei JH; Li X; He L; Sun SG
Zhonghua Yi Xue Za Zhi; 2004 Nov; 84(21):1791-5. PubMed ID: 15631776
[TBL] [Abstract][Full Text] [Related]
13. Prevention of cyclophosphamide-induced accelerated diabetes in the NOD mouse by nicotinamide or a soy protein-based infant formula.
Reddy S; Karanam M; Robinson E
Int J Exp Diabetes Res; 2001; 1(4):299-313. PubMed ID: 11467420
[TBL] [Abstract][Full Text] [Related]
14. Early nicotinamide treatment in the NOD mouse: effects on diabetes and insulitis suppression and autoantibody levels.
Reddy S; Bibby NJ; Elliott RB
Diabetes Res; 1990 Oct; 15(2):95-102. PubMed ID: 2151892
[TBL] [Abstract][Full Text] [Related]
15. Protection of IFN-gamma signaling-deficient NOD mice from diabetes by cyclophosphamide.
Mori Y; Kato T; Kodaka T; Kanagawa EM; Hori S; Kanagawa O
Int Immunol; 2008 Sep; 20(9):1231-7. PubMed ID: 18644830
[TBL] [Abstract][Full Text] [Related]
16. Transfusion of apoptotic beta-cells induces immune tolerance to beta-cell antigens and prevents type 1 diabetes in NOD mice.
Xia CQ; Peng R; Qiu Y; Annamalai M; Gordon D; Clare-Salzler MJ
Diabetes; 2007 Aug; 56(8):2116-23. PubMed ID: 17496235
[TBL] [Abstract][Full Text] [Related]
17. Effects of sodium fusidate in animal models of insulin-dependent diabetes mellitus and septic shock.
Nicoletti F; Zaccone P; Di Marco R; Magro G; Grasso S; Morrone S; Santoni A; Tempera G; Meroni PL; Bendtzen K
Immunology; 1995 Aug; 85(4):645-50. PubMed ID: 7558161
[TBL] [Abstract][Full Text] [Related]
18. In vivo blockade of the Fas-Fas ligand pathway inhibits cyclophosphamide-induced diabetes in NOD mice.
Mahiou J; Walter U; Lepault F; Godeau F; Bach JF; Chatenoud L
J Autoimmun; 2001 Jun; 16(4):431-40. PubMed ID: 11437491
[TBL] [Abstract][Full Text] [Related]
19. Acceleration of the development of diabetes in obese diabetic (db/db) mice by nicotinamide: a comparison with its antidiabetic effects in non-obese diabetic mice.
Piercy V; Toseland CD; Turner NC
Metabolism; 2000 Dec; 49(12):1548-54. PubMed ID: 11145115
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-1 beta induced transient diabetes mellitus in rats. A model of the initial events in the pathogenesis of insulin-dependent diabetes mellitus?
Reimers JI
Dan Med Bull; 1998 Apr; 45(2):157-80. PubMed ID: 9587701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
